332,000 Shares in Progyny, Inc. (NASDAQ:PGNY) Bought by Atika Capital Management LLC

Atika Capital Management LLC purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 332,000 shares of the company’s stock, valued at approximately $5,727,000.

Several other institutional investors have also added to or reduced their stakes in PGNY. Signaturefd LLC raised its stake in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after acquiring an additional 1,355 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after buying an additional 1,246 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after buying an additional 1,526 shares during the last quarter. Caitlin John LLC increased its stake in shares of Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after buying an additional 3,183 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in shares of Progyny during the fourth quarter valued at approximately $74,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PGNY shares. BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, March 31st. JPMorgan Chase & Co. increased their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Bank of America lifted their price objective on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group increased their target price on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Progyny has a consensus rating of “Hold” and a consensus target price of $23.64.

Progyny Price Performance

PGNY opened at $22.60 on Friday. The stock has a 50-day moving average price of $22.19 and a 200-day moving average price of $18.50. The firm has a market cap of $1.93 billion, a PE ratio of 38.97, a P/E/G ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $36.36.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.